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Abstract
We implemented 2-D DIGE technology on proteins prepared from serum obtained from children with hand, foot and mouth disease
(HFMD) and controls, to study the differentially expressed proteins in control and HFMD serum samples. Proteins found to be differen-
tially expressed were identiﬁed with matrix-assisted laser desorption/ionization time-of-ﬂight/ time-of-ﬂight mass spectrometry (MALDI-
TOF/TOF MS) analysis. We identiﬁed 30 proteins from mild HFMD samples and 39 proteins from severe HFMD samples, compared
with the normal controls. 25 proteins among them (14 up-regulated and 11 down-regulated proteins) are found in both HFMD groups.
Classiﬁcation analysis and protein–protein interaction map showed that they associate with multiple functional groups, including trans-
porter activity and atalytic activity. These ﬁndings build up a comprehensive proﬁle of the HFMD proteome and provide a useful basis
for further analysis of the pathogenic mechanism and the regulatory network of HFMD.
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Introduction
Hand, foot and mouth disease (HFMD), a highly infectious
disease that mainly affects children <5 years old, is charac-
terized by fever, papules on the hands and feet, and mouth
ulcers. It can be caused by viruses that belong to the
enterovirus genus (group), including polioviruses, coxsacki-
eviruses, echoviruses and enteroviruses [1]. Among them,
Coxsackieviruses 16 (CA16) and enterovirus 71 (EV71)
have been identiﬁed as the most frequent pathogens of
HFMD [2]. The virus transmits through a direct contact
with mucous, oral or nasal secretions or faeces of an
infected person. HFMD patients with or without symptoms
are the major infectious sources [3]. The disease causes
fever, tetter on the hands and feet and ulceration in the
mouth, and may further develop into myocarditis, pulmo-
nary oedema, aseptic meningoencephalitis and other compli-
cations [4,5].
Since the ﬁrst HFMD case was reported in New Zealand
in 1957, subsequent outbreaks have been reported world-
wide. Historically, the outbreaks of HFMD were reported
spontaneously and at a small scale in European countries and
the United States [6]. Since 1997, large epidemic outbreaks
of HFMD associated with severe neurological complications
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and high mortality rates have occurred in Malaysia, Taiwan,
Singapore, Japan and other Asian-Paciﬁc areas. Large out-
breaks of HFMD have been reported since 2008 in mainland
China, resulting in millions of infections and hundreds of
deaths in children [2]. Noticeably, both the number of
severe cases and mortality rate for HFMD have signiﬁcantly
increased in recent years and the epidemics of HFMD pose
serious public health threats to children throughout the
world [7,8]. Although treatment has been improved with the
application of new technologies, there is currently no speciﬁc
antiviral therapy to cure HFMD and no vaccine to prevent
severe HFMD infection [2].
Usually the enterovirus exhibits strong transitivity; more-
over, the recent infection rate is high and the transmission
paths are complicated, causing large epidemics in a short
period of time. Screening and identiﬁcation of HFMD play
important roles in preventing its occurrence and develop-
ment. Therefore rapid and accurate diagnosis is very impor-
tant. Serum is rich in protein composition which changes in
abundance during different stages. Discovering molecular
markers from serum may be valuable in the early diagnosis
of HFMD.
Proteomics analysis is currently considered to be a pow-
erful tool for global evaluation of protein expression, and
has been widely applied in studying biomarkers for diseases
[9]. Two-dimensional ﬂuorescence difference gel electro-
phoresis (2D-DIGE), a new proteomics technology, has
been developed in recent years. It shows signiﬁcantly
improved sensitivity and repeatability when compared with
the traditional two-dimensional electrophoresis. It is a new
means to provide an overall view of the proteome of the
disease.
A recent study carried out a comparative proteome anal-
ysis between EV71 and CA16, the two most causative
agents of HFMD in cultured human rhabdomyosarcoma
(RD) host cells [10]. The study showed the effect of the
viral infection (e.g. active shutting down of the protein syn-
thesis of the host cell), as well as cellular response to the
viral infection, such as the intracellular immune response.
The study also provided interesting molecular explanations
of the disease phenotype, such as loss of muscle tone
caused by down-regulated HSP27 and desmin. However, the
study focused on the intracellular differentially expressed
proteins using cancer cell lines, which deviates from the in
vivo situation. Moreover, the infection may cause a series of
responses by multiple cell types in the human body, which is
far more complex than the cell line model. Also, there is no
analysis of the extracellular proteins in infected cells. In this
study, we aim to identify potential proteins as biomarkers in
HFMD serum samples using 2D-DIGE and matrix-assisted
laser desorption/ionization time-of-ﬂight/ mass spectrometry
(MALDI-TOF MS) methodologies to identify differentially
expressed proteins in HFMD compared with normal serum
samples and further to determine the possible molecular
markers for HFMD. Classiﬁcation analysis of the proteins
identiﬁed based on the PANTHER and protein–protein
interaction analysis indicated that these proteins might have
important roles in a variety of cellular processes and struc-
tures, including spermatogenesis, cell signalling, cell skeleton
and metabolism.
Materials and Methods
Preparation of serum samples
Blood samples from 16 HFMD children (eight mild and eight
severe) according to the ‘foot and mouth disease prevention
control guide’ (2008 Edition) issued by the Ministry of Health,
China (http://www.moh.gov.cn/publicﬁles/business/htmlﬁles/moh
bgt/s9511/200805/34775.htm.), were randomly selected to be
analysed. These children were proven to have no other dis-
ease after a series of checks in the hospital. Clinical symp-
toms and laboratory test (Enterovirus 71 (EV71) nucleic acid
detection kit) conﬁrmed that the EV71 infections caused all
these HFMD cases. Another eight blood samples from normal
children were collected as controls. A pooled sample consist-
ing of equal amounts of each of 16 experimental samples
(mild HFMD compared with normal control; severe HFMD
compared with normal control) was used as a pooled internal
standard. Serum was separated by centrifugation at 800 g for
30 min. Aliquots of serum were collected and stored at
)80C until ready for use. Serum samples were processed
using the ProteoPrep Blue Albumin Depletion Kit (Sigma, St.
Louis, MO, USA), which selectively removes albumin and IgG
from the serum sample according to the manufacturer’s
instructions. To depurate the protein extraction and deter-
mine the ﬁnal protein concentration, the 2-D Clean-up Kit
(GE Healthcare, UK) and 2-D Quant Kit (GE Healthcare,
London, UK) were used sequentially, following the manufac-
turer’s instructions.
Protein labelling with CyDye DIGE ﬂuor
Protein extracts were labelled with three CyDye DIGE ﬂu-
ors, Cy2, Cy3 and Cy5, for 2-D DIGE technology according
to the manufacturer’s recommended protocols. A total of
50 lg of protein from a normal sample was labelled with
400 pmol of Cy3, and 50 lg of protein from a mild HFMD
sample or severe HFMD sample was labeled with 400 pmol
of Cy5. An internal reference standard, consisting of two
mixed samples used in the experiment, was labelled with
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Cy2. The labelling reaction was incubated on ice for 30 min
under dark conditions. The reactions were then quenched
with the addition of 10 mM lysine for 10 min on ice in the
dark. The labelled samples were pooled and prepared for
the subsequent steps of the experiment.
2-D electrophoresis
2-D electrophoresis was performed as described earlier with
a few minor modiﬁcations [11]. Immobilized pH gradient
(IPG) strips (24 cm, pH 4–7) were hydrated in hydration buf-
fer (7 M urea, 2 M thiourea, 4% w/v CHAPS, 40 mM DTT,
1% IPG buffer, pH 4–7 and 0.002% w/v Bromophenol blue)
and isoelectric focusing (IEF) was performed according to
the manufacturer’s instructions using pH 4–7 IPG strips with
an Ettan IPGphor II System (GE Healthcare). After the iso-
electric focusing (IEF), the proteins were reduced and alkyl-
ated by successive treatment for 15 min with equilibration
buffer containing 2% w/v DTT followed by 2.5% w/v IAA.
Second-dimension separation was performed on a 12.5%
SDS-PAGE gel using an Ettan DALT six instrument (GE
Healthcare).
Gel image acquisition and analysis
Labelled proteins were visualized using the Typhoon 9400
imager (GE Healthcare) and analysed using DeCyder Soft-
ware (V6.0; GE Healthcare) as described previously [12,13].
Brieﬂy, the Cy2, Cy3 and Cy5 labelled images for each gel
were scanned with excitation/emission wavelengths of 488/
520, 532/580 and 633/670 nm, respectively. After the CyDye
labelling, signals were imaged, and the gels were stained using
Deep Purple total protein stain (GE Healthcare) according to
the standard protocol and scanned with excitation/emission
wavelengths of 532/560 nm. Then, 2-D DIGE gel images
were analysed with DeCyder software. The protein expres-
sion patterns of mild HFMD or severe HFMD serum samples
were compared with the control (control vs. mild HFMD or
control vs. severe HFMD). Protein spots with signiﬁcant dif-
ferences in abundance (more than 1.5-fold) [14] were
selected in the stained gels for spot picking.
Spot picking and enzymatic digestion
Protein spot-features that were signiﬁcantly (p <0.05)
increased or decreased in all HFMD samples compared with
control samples were chosen for further analysis. Three pre-
parative gels were performed to enable recovery of sufﬁcient
protein within the individual spot feature to allow protein
identiﬁcation. In the automated procedure, the selected pro-
tein spots were picked up, washed with 25 mM NH4HCO3
and 50% v/v methanol and then digested with 12.5 ng/mL tryp-
sin (Sequencing-grade; Promega, Madison, WI, USA) in 25 mM
NH4HCO3 for 12 h at 37C. The tryptic peptides were
extracted with 60%v/v ACN and 0.1% v/v TFA, then dissolved
in 4 mg/mL CHCA matrix in 70% (v/v) ACN and 0.1% (v/v)
TFA and spotted on the mass spectrometry (MS) sample plate.
MALDI-TOF/TOF MS analysis
MS analysis was performed on an Utraﬂex III MALDI-TOF/
TOF MS (Bruker, Karlsruhe, Baden-Wu¨rttemberg, Germany)
operating in positive ion reﬂector mode. Monoisotopic peak
masses were acquired in a mass range of 700–4000 Da with a
signal-to-noise ratio (S/N) >200. Four of the most intense ion
signals, excluding common trypsin autolysis peaks and matrix
ion signals, were automatically selected as precursors for MS/
MS acquisition. The peptide mass ﬁngerprint combined MS/
MS spectra were searched against the NCBInr database using
the Biotools software (Version 3.2; Bruker) and MASCOT
Version 2.2 (Matrix Science, Boston, MA, USA) with the fol-
lowing parameters: Homo sapiens, trypsin cleavage, one
missed cleavage allowed, carbamidomethylation as ﬁxed mod-
iﬁcation, oxidation of methionines allowed as variable modiﬁ-
cation, peptide mass tolerance at 100 ppm, fragment
tolerance at 0.7 Da. The criteria for successfully identiﬁed
proteins include: ion score conﬁdence interval (CI %) for
PMF, MS/MS data ‡95%; a minimum of four peptides hits
required in PMF data-based identiﬁcation; and at least two
peptides of distinct sequence identiﬁed.
Database searching
The MS/MS spectra were searched using MASCOT to search
human and EV71 protein databases to identify proteins. The
following peptide search criteria were employed: species:
Homo sapiens and EV71 virus, trypsin digest (one missed
cleavage allowed), peptide tolerance: 100 ppm, mass value:
monoisotropic, protein mass ranged from 1 to 100 kDa.
NCBI databases were searched. Protein identiﬁcation by
PMF was performed using the MASCOT search engine.
Protein categorization
The identiﬁed proteins were classiﬁed according to the
PANTHER (Protein ANalysis THrough Evolutionary Relation-
ships) system (http://www.pantherdb.org), which classiﬁes
genes and proteins by their functions. The PANTHER ontol-
ogy, a highly controlled vocabulary (ontology terms) by
molecular function, biological process and molecular path-
way, was employed to categorize proteins into families and
subfamilies with shared functions.
Predication of protein–protein interaction
The identiﬁed proteins were preceded by the STRING (func-
tional Protein Association Networks) system (http://
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www.string-db.org). STRING is a database of known and
predicted protein interactions, including direct (physical) and
indirect (functional) associations.
Results
2-D DIGE analysis of differential protein expression
The goal of this study was to look for some proteins that
were considered potential biomarkers for early diagnosis of
HFMD. Characterization of HFMD children’s samples from
which serum was obtained for DIGE analysis is presented in
Fig. 1. Samples were processed with the ProteoPrep Blue
Albumin Depletion kit to remove the two most abundant
serum proteins from serum for higher sensitivity to visualize
less abundant proteins. As previously described [15], differ-
ential protein analysis was then performed using 2-D DIGE.
After 2-D DIGE analysis, differential protein spots were
detected using DeCyder analysis software. Protein proﬁles
were compared between the HFMD samples and the control
samples. We selected the numbered spots that were at least
1.5-fold differentially expressed proteins.
MALDI-TOF PMF analysis
A total of 30 differentially expressed proteins (18 up-regu-
lated and 12 down-regulated) were identiﬁed in the mild
HFMD samples compared with the level in control samples.
Thirty-nine differentially expressed proteins (22 up-regulated
and 17 down-regulated) were identiﬁed in the severe
HFMD samples compared with the level in control samples
(Table 1). Table 2 summarizes the 25 proteins that all
appeared in both the mild and severe HFMD samples com-
pared with the level in control samples. Among these, 14
proteins had increased and 11 proteins had decreased in
the HFMD samples compared with the level in control
samples.
Classiﬁcation of identiﬁed proteins
According to cellular functions and processes, the proteins
were distributed into categories based on molecular func-
tion, biological processes involved and protein classes using
the PANTHER classiﬁcation system. The results are shown
in Fig. 2. The most dominant function that the identiﬁed pro-
tein was involved in was transporter activity (28.0%) fol-
lowed by binding (24.0%), enzyme regulator activity (16.0%),
catalytic activity (16.0%) and receptor activity (12.0%). Most
of the identiﬁed proteins played roles in the metabolic pro-
cess (17.3%) and immune system process (15.4%). Other
biological processes that the proteins were involved in
included response to stimulus (11.5%), cellular process
(11.5%), transport (11.5%), etc. As for protein class, most of
the proteins belonged to transporter (40.0%), transfer/car-
rier protein (13.3%) or signalling molecule (13.3%); others
belonged to receptor (6.7%), defence/immunity protein
(a)
(b)
FIG. 1. Analysis of hand, foot and mouth disease (HFMD) samples
as revealed by 2-D DIGE analysis. Proteins extracted from HFMD
and control samples were labelled with Cy3 and Cy5, respectively.
An internal standard protein sample (a mixture of HFMD and con-
trol samples) was labelled with the Cy2 dye. The Cy3-labelled HFMD
samples and the Cy5-labelled control samples were mixed and sepa-
rated on a 2-D DIGE gel (IEF on pH 4–7 strips followed by 12.5%
second dimension SDS-PAGE). The green spots represent down-reg-
ulated proteins, while the red spots represent up-regulated proteins
in HFMD samples compared with the control samples. The yellow
arrow represents the identiﬁed proteins that showed signiﬁcantly dif-
ferential expression in the HFMD and control samples. The number
in the ﬁgure corresponds to that presented in Tables 1 and 2. (a)
Mild HFMD vs control samples. (b) Severe HFMD vs control samples.
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TABLE 1. Differential proteins identiﬁed by mass spectrometry (MS) after 2-D DIGE of the mild and severe hand, foot and
mouth disease (HFMD) samples vs. control samples
Master
No.
Accession
No. Mr pI
MASCOT
score
Coverage
(%)
Av. ratio t-test
Mw Proteins
Mild
HFMD
Severe
HFMD
Mild
HFMD
Severe
HFMD
272 gi|896277 11776 4.9 37 28 )1.51 — 0.0036 — 130 This CDS feature is included to
show the translation of the cor
responding V_region. Presently
translation qualiﬁers on the
V_region features are illegal
274 gi|55958063 105606 4.8 134 9 )1.96 )1.66 0.00021 0.0064 130 Inter-alpha (globulin) inhibitor H2
279 gi|119581148 57754 4.82 344 20 )1.89 )1.55 0.00076 0.0085 130 Keratin 9 (epidermolytic
palmoplantar keratoderma)
422 gi|134105218 85583 6.32 339 20 1.63 — 0.0067 — 111 Chain A, human complement
factor B
442 gi|224053 162072 5.45 234 5 )2.24 )2.25 0.0023 0.0023 109 Macroglobulin alpha2
480 gi|177870 164600 6.26 582 13 )2.1 )1.7 0.00047 0.0028 107 Alpha-2-macroglobulin precursor
552 gi|4501987 70963 5.3 332 27 )1.62 )1.65 0.0083 0.012 97 Afamin precursor
716 gi|2258128 61728 5.26 304 20 — 1.7 — 0.0057 68 Complement 9
912 gi|6573461 37499 6.12 122 17 )1.7 )1.52 0.0075 0.0034 62 Chain A, crystal structure of
human beta-2-glycoprotein-I
(apolipoprotein-H)
1083 gi|16418467 38382 4.54 324 14 1.76 1.59 0.01 0.012 51 Leucine-rich alpha-2-glycoprotein
1 precursor
1103 gi|113197968 48171 4.49 115 6 — 1.69 — 0.013 49 KRT9 protein
1137 gi|27692693 48641 5.99 104 24 — )1.64 — 0.0049 46 ALB protein
1163 gi|169214179 45642 5.09 304 31 — 1.75 — 0.038 42 Predicted: similar to complement
component 3
1192 gi|78101271 40204 4.82 220 37 2.02 2.41 0.014 0.012 39 Chain C, human complement
component C3c
1203 gi|15277503 40536 5.38 467 46 — 1.53 — 0.033 38 ACTB protein
1230 gi|47124562 31647 5.61 551 34 — 1.9 — 0.028 37 HP protein
1237 gi|21961605 59020 5.54 346 24 2.08 — 0.032 — 36 Keratin 10
1242 gi|38305346 17032 4.22 37 22 2.64 2.74 0.03 0.0041 36 Antigen MLAA-42
1257 gi|119579599 51388 5.41 265 14 2.77 2.75 0.0062 0.0081 35 Haptoglobin, isoform CRA_b
1258 gi|47124562 31647 5.48 386 23 2.07 2.61 0.014 0.029 36 HP protein
1265 gi|118138017 104913 4.99 628 26 2.16 2.98 0.038 0.046 34 Chain B, human complement
component C3b
1279 gi|118137965 104912 4.97 468 15 1.56 3.4 0.044 0.033 33 Chain B, structure of
complement C3b: insights into
complement activation and
regulation
1288 gi|338305 36997 4.85 432 26 — )1.53 — 0.0075 33 ‘SP40,40’
1291 gi|157831596 44280 5.94 136 26 — )1.59 — 0.025 33 Chain A, Alpha1-Antitrypsin
1293 gi|7770217 33466 5.71 130 39 — 2.03 — 0.015 33 PRO2675
1340 gi|27574252 15928 5.23 39 29 1.6 2.02 0.0085 0.0023 31 Chain B, deoxy haemoglobin
(A-Gly-C:v1m;
B,D:v1m,C93a,N108k)
1342 gi|26665859 16267 5.21 310 44 1.75 1.64 0.0089 0.00084 31 CLU
1347 gi|27754776 33395 6.21 400 50 1.51 — 0.038 — 31 Ficolin 3 isoform 1 precursor
1378 gi|122920512 68408 6.06 194 15 — )1.95 — 0.0087 30 Chain A, human serum albumin
complexed with myristate and
aspirin
1390 gi|119390093 23689 6.41 539 52 2.17 — 0.049 — 30 Chain B, Crig bound to C3c
1423 gi|40737308 48037 5.21 213 7 — 1.82 — 0.029 29 C4B1
1437 gi|170684576 24426 6.49 226 45 2.82 1.95 0.048 0.03 29 Immunoglobulin kappa 4 light
chain
1493 gi|576259 23358 5.44 344 26 1.5 1.58 0.016 0.039 28 Chain A, the structure of
pentameric human serum
amyloid P component
1531 gi|55961583 13327 5.68 112 31 — )1.6 — 0.025 26 Apolipoprotein M
1561 gi|178779 43358 5.25 111 16 )2.37 )2.92 0.0091 0.0056 23 Apolipoprotein A-IV precursor
1566 gi|563320 28141 5.14 264 23 )2.64 )2.96 0.011 0.004 21 Apolipoprotein A-IV
1584 gi|296653 42126 5.86 106 20 2.63 3.89 0.044 0.037 19 hp2-alpha
1591 gi|223092 18672 5.31 53 14 2.9 4.31 0.031 0.029 19 Ceruloplasmin CpF5 fragment
1593 gi|296653 42126 5.57 126 20 — 3.91 — 0.042 18 hp2-alpha
1617 gi|224510585 12996 5.68 461 96 )1.75 )1.97 0.0063 0.00082 16 Chain A, crystal structure of the
apo form of human wild-type
transthyretin
1620 gi|189339646 12740 5.4 246 56 — )1.61 — 0.011 16 Chain A, crystal structure of the
F87mL110M mutant of human
Transthyretin At Ph 4.6.
1664 gi|186972736 8759 4.33 99 24 )2.2 )2.32 0.0013 0.0028 12 Chain A, structure and dynamics
of human apolipoprotein C-Iii
1669 gi|225986 11675 6.29 94 53 24.26 29.28 0.016 0.012 10 Amyloid-related serum protein SAA
1674 gi|14277770 8909 4.6 86 73 )2.15 )2.76 0.014 0.0038 10 Chain A, Nmr structure of
human apolipoprotein C-Ii in
the presence of SDS
‘—’ not detected.
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(6.7%), enzyme modulator (6.7%), protease (6.7%) or struc-
tural protein (6.7%) (Fig. 2a–c).
Protein–protein interaction network
The protein interaction network for the identiﬁed proteins
was constructed by STRING (Fig. 3) in order to better
understand the pathogenic mechanisms in HFMD. Biological
systems can be modelled as complex network systems with
many interactions among the components in different path-
ways. These interactions provide us with essential informa-
tion about the function and behaviour of the analysed system.
Discussion
Treatment of HFMD is currently symptomatic, and mild
HFMD resolves spontaneously without complications within
7–10 days. However, severe HFMD can cause severe neuro-
logical symptoms and complications, such as acute ﬂaccid
paralysis, aseptic meningitis and neurogenic pulmonary
oedema. In recent years, although treatment has been
updated with the application of new technologies, there is
currently no speciﬁc antiviral therapy to cure and no vaccine
to prevent severe HFMD infection. Therefore, early detec-
tion of severe HFMD is important and precise staging is nec-
essary for assessing the risk of progression and planning the
appropriate treatment.
Due to the limited practicability of clinical markers for
early diagnosis, the focus of HFMD investigation has shifted to
molecular markers. Protein proﬁles of speciﬁc stages can be
more accurate in reﬂecting the status of disease progression.
In the present study, we took advantage of DIGE-based pro-
teomics to identify stage-speciﬁc markers that reﬂect the sta-
tus of HFMD. DIGE-based proteomics has the advantages of
adequate sensitivity, high reproducibility, wide linear dynamic
range and minimized experimental variation over traditional
proteomics because of internal standards and ﬂuorescence
labelling. Although no protein identiﬁed was reported to have
direct connection to HFMD the majority of the differentially
expressed proteins are involved in the host immune response
system, inﬂammation and protein aggregation.
ITIH2 (inter-alpha (globulin) inhibitor H2), A2M (macro-
globulin alpha2), etc. (protease inhibitors), were suggested to
be involved in the viral infection. ITIH2 belongs to the inter-
alpha-trypsin inhibitors (ITI) family, which is involved in
extracellular matrix stabilization and the host-virus interac-
tion process. A2M, a multifunctional protease inhibitor and
cytokine transporter, inhibits various proteases, including
trypsin, thrombin and collagenase, and is an essential compo-
nent in salivary innate immunity against haemaglutination
mediated by S-OIV [16]. LRG1 (leucine-rich alpha-2-glyco-
protein 1 precursor) belongs to the leucine-rich repeat
(LRR) family of proteins, which is expressed during granulo-
cyte differentiation [17], indicating that LRG1 might play a
role in the immune response when the host clears infections.
The up-regulation of LRG1 and down-regulation of ITIH2
and A2M suggests the immune response to infection with
HFMD.
TABLE 2. Differential proteins identiﬁed all appeared by mass spectrometry (MS) after 2-D DIGE in both the mild and severe
hand, foot and mouth disease samples vs. control samples
Master no Accession No. Mr pI Mw Proteins
274 gi|55958063 105606 4.8 130 Inter-alpha (globulin) inhibitor H2
279 gi|119581148 57754 4.82 130 Keratin 9 (epidermolytic palmoplantar keratoderma)
442 gi|224053 162072 5.45 109 Macroglobulin alpha2
480 gi|177870 164600 6.26 107 Alpha-2-macroglobulin precursor
552 gi|4501987 70963 5.3 97 Afamin precursor
912 gi|6573461 37499 6.12 62 Chain A, crystal structure of human beta-2-glycoprotein-I (Apolipoprotein-H)
1083 gi|16418467 38382 4.54 51 Leucine-rich alpha-2-glycoprotein 1 precursor
1192 gi|78101271 40204 4.82 39 Chain C, human complement component C3c
1242 gi|38305346 17032 4.22 36 Antigen MLAA-42
1257 gi|119579599 51388 5.41 35 Haptoglobin, isoform CRA_b
1258 gi|47124562 31647 5.48 36 HP protein
1265 gi|118138017 104913 4.99 34 Chain B, human complement component C3b
1279 gi|118137965 104912 4.97 33 Chain B, structure of complement C3b: insights into complement activation and regulation
1340 gi|27574252 15928 5.23 31 Chain B, deoxy haemoglobin (A-Gly-C:v1m; B,D:v1m,C93a,N108k)
1342 gi|26665859 16267 5.21 31 CLU
1437 gi|170684576 24426 6.49 29 Immunoglobulin kappa 4 light chain
1493 gi|576259 23358 5.44 28 Chain A, the structure of pentameric human serum amyloid P component
1561 gi|178779 43358 5.25 23 Apolipoprotein A-IV precursor
1566 gi|563320 28141 5.14 21 Apolipoprotein A-IV
1591 gi|223092 18672 5.31 19 Ceruloplasmin CpF5 fragment
1593 gi|296653 42126 5.57 18 hp2-alpha
1617 gi|224510585 12996 5.68 16 Chain A, crystal structure of the apo form of human wild-type transthyretin
1664 gi|186972736 8759 4.33 12 Chain A, structure and dynamics of human apolipoprotein C-Iii
1669 gi|225986 11675 6.29 10 Amyloid related serum protein SAA
1674 gi|14277770 8909 4.6 10 Chain A, Nmr structure of human apolipoprotein C-Ii in the presence of SDS
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Interestingly, A2M is also involved in the amyloid response
in Alzheimer’s disease together with apolipoproteins [18].
These proteins bind the misfolded Ab and the complex is
then cleared by LRP1 (low density lipoprotein receptor-
related protein 1). Down-regulation of A2M in HFMD
decreases the amyloid clearance. APCS (chain A, the struc-
ture of pentameric human serum amyloid P component) and
TTR (chain A, crystal structure of the apo form of human
wild-type transthyretin), which were found to be up-regu-
lated in HFMD patients, are also related to protein aggrega-
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FIG. 2. Classiﬁcation analysis of proteins found in hand, foot and mouth disease (HFMD) samples. Categorization was based on information that
was obtained from the online PANTHER classiﬁcation system. (a) Classiﬁcation of the identiﬁed proteins of HFMD samples according to the
molecular function. (b) Classiﬁcation of the identiﬁed proteins of HFMD samples according to the biological processes. (c) Classiﬁcation of the
identiﬁed proteins of HFMD samples according to the protein class.
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tion. APCS is a universal constituent of the abnormal tissue
deposits in amyloidosis, and its glycosylated form is resistant
to degradation, causing the amyloid deposits to remain [19].
Extracellular deposition of wild-type TTR caused by transthy-
retin amyloidosis leads to amyloid ﬁbril formation in various
tissues and organs, and may further result in failure of organs
(e.g. heart failure) [20,21]. SAA, which was found to be the
most up-regulated (more than 20-fold) in both mild and
severe HFMD, was reported to be closely related to tissue
damage or inﬂammation (may increase 1000-fold) [22]. Inter-
estingly, SAA is also found to be elevated in Alzheimer’s
disease and Down’s syndrome, especially in the prolonged
stage [23]. As an acute phase protein, SAA is found in only
some patients with early-stage AD; however, the inﬂamma-
tion may impair Ab clearance due to the loss of apoE from
CSF-HDL [23,24]. These ﬁndings strongly suggested that the
amyloidosis, including increasing of the amyloidgenic material
(TTR), increasing of the amyloid-stabilizing factor (APCS) and
decreasing of the amyloid clearance (A2M and SAA), may be
an important molecular event in HFMD.
When comparing with the previous study using a cultured
cancer cell line [10], b-actin is the only protein among their
ﬁndings which appears in our study. In our study, we found
that b-actin was up-regulated in the serum of the severe
HFMD patients. b-Actin is an intracellular protein. Its
increase in serum may indicate cell death caused by serious
infection.
In the current study, although none of the above-men-
tioned differentially expressed proteins is speciﬁcally corre-
lated with HFMD, the combination of their variations may
still serve as a useful hint for diagnosis of early-stage HFMD
prior to the appearance of severe symptoms.
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